首页> 外文期刊>The Breast : >Interest and attitudes of patients, cancer physicians, medical students and cancer researchers towards a spectrum of genetic tests relevant to breast cancer patients
【24h】

Interest and attitudes of patients, cancer physicians, medical students and cancer researchers towards a spectrum of genetic tests relevant to breast cancer patients

机译:患者,癌症医师,医学生和癌症研究人员对与乳腺癌患者相关的一系列基因检测的兴趣和态度

获取原文
获取原文并翻译 | 示例
       

摘要

The perspectives of patients and healthcare professionals towards breast cancer genetic tests that are becoming increasingly available is unexplored in Asians. We surveyed the interest and attitudes of 200 breast cancer patients, 67 cancer physicians, 485 medical students and cancer researchers towards three genetic tests, BRCA1/2 mutation, CYP2D6 genotype and Oncotype DX testing, using hypothetical scenarios. Approximately 60% of patients expressed initial interest in each genetic test, although the majority reversed their decisions once test limitations were conveyed, with <15% maintaining interest in each test. Cancer physicians were most likely to recommend BRCA1/2 mutation testing (73%) and least likely to recommend CYP2D6 genotyping (12%), while patients were more likely to choose Oncotype DX testing (28%) over CYP2D6 (21%) and BRCA1/2 testing (15%). Cost concerns, low educational level and lack of prior awareness of genetic testing were the main barriers against breast cancer genetic testing among Asian patients.
机译:在亚洲人中,患者和医疗保健专业人员对乳腺癌基因检测的观点日益普及。我们使用假设的情景,调查了200名乳腺癌患者,67名癌症医师,485名医学生和癌症研究人员对三种基因测试,BRCA1 / 2突变,CYP2D6基因型和Oncotype DX测试的兴趣和态度。大约60%的患者对每种基因检测表达了最初的兴趣,尽管一旦传达了检测限制,大多数患者就改变了他们的决定,其中只有不到15%的患者对每种检测保持了兴趣。癌症医生最可能建议进行BRCA1 / 2突变检测(73%),最不建议进行CYP2D6基因型检测(12%),而患者更倾向于选择Oncotype DX检测(28%),而不是CYP2D6(21%)和BRCA1。 / 2测试(15%)。成本问题,低学历和缺乏对基因检测的事先了解是亚洲患者乳腺癌基因检测的主要障碍。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号